FOTO: Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment Versus Continuous Treatment
A Randomized Controlled Trial of a Weekly Schedule of Five Consecutive Days on Treatment With Efavirenz, Tenofovir, and Emtricitabine Followed by Two Days Off Treatment (5/2 Intermittent Treatment Schedule) Versus Continuous Treatment in Individuals With Virologic Suppression on This Combination
Sponsor: Community Research Initiative of New England
Listed as NCT00414635, this PHASE4 trial focuses on HIV Infections and remains completed. Sponsored by Community Research Initiative of New England, it has been updated 10 times since 2006, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Dec 2021 — Dec 2022 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Sep 2017 [monthly]
Completed PHASE4
First recorded
Aug 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Community Research Initiative of New England
- The Campbell Foundation
For direct contact, visit the study record on ClinicalTrials.gov .